Enoximone
Clinical data
Trade namesPerfan
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability50% (oral)
Protein binding85%
MetabolismLiver (oxidation)
Elimination half-life4 to 10 hours
ExcretionRenal (60 to 70%)
Identifiers
  • 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H12N2O2S
Molar mass248.30 g·mol−1
3D model (JSmol)
Melting point255 to 258 °C (491 to 496 °F) (decomposes)
  • O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
  • InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) checkY
  • Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N checkY
  (verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.[1]

References

  1. ↑ Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID 17714066. S2CID 46021219.
  • Media related to Enoximone at Wikimedia Commons


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.